CDx provides non-invasive biopsies for common oral lesions to rule out dysplasia or cancer, preventing cancer of the oral cavity, pharynx, larynx, and esophagus through early detection of their easily treatable, pre-cancerous precursors. The company's diagnostic platform synthesizes computer imaging, artificial intelligence, molecular biology, and three-dimensional cytopathology to detect precancerous changes earlier and more reliably than prior methods. CDx testing is highly cost-effective, widely reimbursed, and addresses a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Additionally, WATS3D, a subsidiary of CDx, provides a more effective alternative to current random forceps biopsy testing of the esophagus, increasing the detection rate of both Barrett's esophagus and esophageal dysplasia through a proprietary 3-Dimensional computer imaging system based on an artificial intelligence algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program.